Commentary: rapamycin for the aging skin
- PMID: 32227278
- PMCID: PMC7206468
- DOI: 10.1007/s11357-020-00184-2
Commentary: rapamycin for the aging skin
Abstract
A response is provided to a commentary on a recent study examining the impact of low-dose topical application of rapamycin on markers of aging in the skin. The barriers to clinical implementation of therapies targeting the fundamental aging process are discussed, and the topical study is placed in context with the broader effort to develop new therapeutics for age-related disorders.
Comment on
-
Topical rapamycin reduces markers of senescence and aging in human skin: an exploratory, prospective, randomized trial.Geroscience. 2019 Dec;41(6):861-869. doi: 10.1007/s11357-019-00113-y. Epub 2019 Nov 25. Geroscience. 2019. PMID: 31761958 Free PMC article. Clinical Trial.
-
Rapamycin for the aging skin.Aging (Albany NY). 2019 Dec 27;11(24):12822-12826. doi: 10.18632/aging.102664. Epub 2019 Dec 27. Aging (Albany NY). 2019. PMID: 31895693 Free PMC article. No abstract available.
References
-
- Chung CL, Lawrence I, Hoffman M, Elgindi D, Nadhan K, Potnis M, Jin A, Sershon C, Binnebose R, Lorenzini A, Sell C. Topical rapamycin reduces markers of senescence and aging in human skin: an exploratory, prospective, randomized trial. Geroscience. 2019;41:861–869. doi: 10.1007/s11357-019-00113-y. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
